Marcelo Mazza Do Nascimento
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marcelo Mazza Do Nascimento has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
- José Andrade Moura Neto
Sociedade Brasileira de Nefrologia
8 shared publications - Andrea Pio-Abreu
Universidade de São Paulo, Brazil
7 shared publications - Dirceu Reis da Silva
Hospital de Clínicas de Porto Alegre, Brazil
5 shared publications - Jocemir Ronaldo Lugon
Universidade Federal Fluminense, Niterói, RJ, Brazil
5 shared publications - Kleyton de Andrade Bastos
Sociedade Brasileira de Nefrologia, Brazil; Universidade Federal de Sergipe, Brazil
5 shared publications - Ricardo Sesso
Federal University of São Paulo, São Paulo, Brazil
5 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 48 (4)
Microeliminação da hepatite C em unidades de diálise: resultados do Registro Brasileiro para eliminação do HCV
Resumo Introdução: A infecção pelo vírus da hepatite C (HCV) é um desafio de saúde pública, especialmente em pacientes em diálise, que apresentam maior vulnerabilidade e risco de transmissão. A estratégia de microeliminação em subgrupos de alto risco é fundamental para atingir as metas globais da Organização Mundial da Saúde. Métodos: Trata-se de um estudo nacional de implementação, multicêntrico e prospectivo, fundamentado no Registro Brasileiro para Eliminação da Hepatite C em Unidades de Diálise. As 904 unidades de diálise ativas do país foram convidadas; 384 (42,5%) aderiram voluntariamente e, em cada uma, todos os pacientes elegíveis foram arrolados entre 2021 e 2024. Avaliou-se a cascata de cuidado: rastreamento sorológico (anti-HCV), confirmação virológica (RNA-HCV), tratamento com antivirais de ação direta (DAAs) e resposta virológica sustentada (SVR). Resultados: Foram avaliados 66.601 pacientes, com prevalência nacional de anti-HCV de 2,08%. A cobertura de testagem para RNA-HCV foi de 65,4%, com positividade de 64,2% entre os testados, resultando em uma prevalência ajustada de viremia de 1,34%. Dos pacientes com viremia detectada, 74,2% iniciaram o tratamento, 92,6% completaram o esquema e 93,3% alcançaram a SVR. As principais barreiras incluíram indisponibilidade de exames e óbito. Discussão: Os resultados demonstram que o Brasil possui indicadores robustos de eficácia terapêutica, situando o país em estágio avançado para a eliminação do HCV na população dialítica. No entanto, persistem gargalos operacionais na confirmação diagnóstica. Conclusão: A eliminação do HCV em unidades de diálise é uma meta factível no Brasil. O sucesso depende da manutenção do rastreio universal, do tratamento imediato dos casos confirmados e da integração contínua entre a nefrologia e a hepatologia.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 48 (4)
Open AccessMicroeliminação da hepatite C em unidades de diálise: resultados do Registro Brasileiro para eliminação do HCV
Resumo Introdução: A infecção pelo vírus da hepatite C (HCV) é um desafio de saúde pública, especialmente em pacientes em diálise, que apresentam maior vulnerabilidade e risco de transmissão. A estratégia de microeliminação em subgrupos de alto risco é fundamental para atingir as metas globais da Organização Mundial da Saúde. Métodos: Trata-se de um estudo nacional de implementação, multicêntrico e prospectivo, fundamentado no Registro Brasileiro para Eliminação da Hepatite C em Unidades de Diálise. As 904 unidades de diálise ativas do país foram convidadas; 384 (42,5%) aderiram voluntariamente e, em cada uma, todos os pacientes elegíveis foram arrolados entre 2021 e 2024. Avaliou-se a cascata de cuidado: rastreamento sorológico (anti-HCV), confirmação virológica (RNA-HCV), tratamento com antivirais de ação direta (DAAs) e resposta virológica sustentada (SVR). Resultados: Foram avaliados 66.601 pacientes, com prevalência nacional de anti-HCV de 2,08%. A cobertura de testagem para RNA-HCV foi de 65,4%, com positividade de 64,2% entre os testados, resultando em uma prevalência ajustada de viremia de 1,34%. Dos pacientes com viremia detectada, 74,2% iniciaram o tratamento, 92,6% completaram o esquema e 93,3% alcançaram a SVR. As principais barreiras incluíram indisponibilidade de exames e óbito. Discussão: Os resultados demonstram que o Brasil possui indicadores robustos de eficácia terapêutica, situando o país em estágio avançado para a eliminação do HCV na população dialítica. No entanto, persistem gargalos operacionais na confirmação diagnóstica. Conclusão: A eliminação do HCV em unidades de diálise é uma meta factível no Brasil. O sucesso depende da manutenção do rastreio universal, do tratamento imediato dos casos confirmados e da integração contínua entre a nefrologia e a hepatologia.
- Open Access
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 48 (4)
Microelimination of hepatitis C in dialysis units: results from the Brazilian Registry for the elimination of HCV
Introduction: Hepatitis C virus (HCV) infection remains a major public health challenge, particularly among patients undergoing dialysis, who are disproportionately vulnerable and at increased risk of transmission. Micro-elimination strategies targeting high-risk subpopulations are a critical component for achieving the World Health Organization global HCV elimination goals. Methods: This national, multicenter, prospective implementation study was conducted within the framework of the Brazilian Registry for the Elimination of HCV in Dialysis Units. All 904 active dialysis units in the country were invited; 384 (42.5%) joined voluntarily, and, within each, all eligible patients were enrolled (census) between 2021 and 2024. The HCV cascade of care was evaluated, including serological screening (anti-HCV), virological confirmation (HCV-RNA), treatment with direct-acting antivirals (DAAs), and assessment of sustained virologic response (SVR). Results: A total of 66,601 patients were evaluated, yielding a national anti-HCV prevalence of 2.08%. HCV-RNA testing coverage reached 65.4%, with a positivity rate of 64.2% among those tested, resulting in an adjusted prevalence of active viremia of 1.34%. Among patients with detectable viremia, 74.2% initiated antiviral therapy, 92.6% completed treatment, and 93.3% achieved SVR. The main barriers identified along the cascade of care included limited availability of diagnostic tests and patient mortality. Discussion: These findings indicate that Brazil has achieved robust therapeutic effectiveness indicators, placing the country at an advanced stage toward HCV elimination within the dialysis population. Nonetheless, important operational gaps persist, particularly in diagnostic confirmation. Conclusion: Elimination of HCV in dialysis units is an achievable goal in Brazil. Sustained success depends on maintaining universal screening, ensuring prompt treatment initiation for confirmed cases, and strengthening continuous integration between services.
- 1 January 2026
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 48 (4)
Open AccessMicroelimination of hepatitis C in dialysis units: results from the Brazilian Registry for the elimination of HCV
Introduction: Hepatitis C virus (HCV) infection remains a major public health challenge, particularly among patients undergoing dialysis, who are disproportionately vulnerable and at increased risk of transmission. Micro-elimination strategies targeting high-risk subpopulations are a critical component for achieving the World Health Organization global HCV elimination goals. Methods: This national, multicenter, prospective implementation study was conducted within the framework of the Brazilian Registry for the Elimination of HCV in Dialysis Units. All 904 active dialysis units in the country were invited; 384 (42.5%) joined voluntarily, and, within each, all eligible patients were enrolled (census) between 2021 and 2024. The HCV cascade of care was evaluated, including serological screening (anti-HCV), virological confirmation (HCV-RNA), treatment with direct-acting antivirals (DAAs), and assessment of sustained virologic response (SVR). Results: A total of 66,601 patients were evaluated, yielding a national anti-HCV prevalence of 2.08%. HCV-RNA testing coverage reached 65.4%, with a positivity rate of 64.2% among those tested, resulting in an adjusted prevalence of active viremia of 1.34%. Among patients with detectable viremia, 74.2% initiated antiviral therapy, 92.6% completed treatment, and 93.3% achieved SVR. The main barriers identified along the cascade of care included limited availability of diagnostic tests and patient mortality. Discussion: These findings indicate that Brazil has achieved robust therapeutic effectiveness indicators, placing the country at an advanced stage toward HCV elimination within the dialysis population. Nonetheless, important operational gaps persist, particularly in diagnostic confirmation. Conclusion: Elimination of HCV in dialysis units is an achievable goal in Brazil. Sustained success depends on maintaining universal screening, ensuring prompt treatment initiation for confirmed cases, and strengthening continuous integration between services.
- Open Access
- 1 December 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 47 (4)
Troponina I como marcador independente de risco de mortalidade cardiovascular em pacientes com doença renal crônica
Resumo Introdução: Doença cardiovascular (DCV) é a principal causa de óbito entre pacientes com doença renal crônica (DRC). Entretanto, a avaliação prognóstica cardiovascular (CV) na DRC não está estabelecida. Apesar de relatos anteriores estabelecerem a troponina como prognóstico de mortalidade CV na DRC, não há consenso sobre sua aplicabilidade. Além disso, estudos sobre a troponina I de alta sensibilidade (hsTnI) nesse contexto são escassos. Avaliamos a associação entre hsTnI e mortalidade CV e geral entre pacientes com DRC para identificar pacientes com maior risco CV. Métodos: 145 pacientes com DRC estágios 3 a 5 foram submetidos a medições de hsTnI, inflamação, metabolismo do cálcio-fósforo, calcificação vascular e parâmetros ecocardiográficos. A associação entre hsTnI e mortalidade CV e geral após o acompanhamento foi estabelecida por meio de curvas de Kaplan-Meier. O valor de corte da hsTnI para predição de mortalidade CV e geral foi definido com a análise da curva ROC. A análise multivariada para mortalidade CV e geral foi realizada utilizando modelos de regressão de Cox. Resultados: O valor de corte da hsTnI para mortalidade geral e CV foi 0,057 ng/mL. Pacientes com hsTnI mais elevada apresentaram maior mortalidade CV e geral. Na análise multivariada, a hsTnI foi um marcador de mortalidade CV aumentada (razão de risco 12,8 (IC 95% 1,56-105,08); p = 0,018), independente de idade, sexo, DCV anterior, diabetes e diálise, achados ecocardiográficos e osteoprotegerina (OPG). Conclusão: A hsTnI está independentemente associado à mortalidade CV em pacientes com DRC, sugerindo que pode ser um potencial marcador para estratificação de risco CV.
- 1 December 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 47 (4)
Open AccessTroponina I como marcador independente de risco de mortalidade cardiovascular em pacientes com doença renal crônica
Resumo Introdução: Doença cardiovascular (DCV) é a principal causa de óbito entre pacientes com doença renal crônica (DRC). Entretanto, a avaliação prognóstica cardiovascular (CV) na DRC não está estabelecida. Apesar de relatos anteriores estabelecerem a troponina como prognóstico de mortalidade CV na DRC, não há consenso sobre sua aplicabilidade. Além disso, estudos sobre a troponina I de alta sensibilidade (hsTnI) nesse contexto são escassos. Avaliamos a associação entre hsTnI e mortalidade CV e geral entre pacientes com DRC para identificar pacientes com maior risco CV. Métodos: 145 pacientes com DRC estágios 3 a 5 foram submetidos a medições de hsTnI, inflamação, metabolismo do cálcio-fósforo, calcificação vascular e parâmetros ecocardiográficos. A associação entre hsTnI e mortalidade CV e geral após o acompanhamento foi estabelecida por meio de curvas de Kaplan-Meier. O valor de corte da hsTnI para predição de mortalidade CV e geral foi definido com a análise da curva ROC. A análise multivariada para mortalidade CV e geral foi realizada utilizando modelos de regressão de Cox. Resultados: O valor de corte da hsTnI para mortalidade geral e CV foi 0,057 ng/mL. Pacientes com hsTnI mais elevada apresentaram maior mortalidade CV e geral. Na análise multivariada, a hsTnI foi um marcador de mortalidade CV aumentada (razão de risco 12,8 (IC 95% 1,56-105,08); p = 0,018), independente de idade, sexo, DCV anterior, diabetes e diálise, achados ecocardiográficos e osteoprotegerina (OPG). Conclusão: A hsTnI está independentemente associado à mortalidade CV em pacientes com DRC, sugerindo que pode ser um potencial marcador para estratificação de risco CV.
- Open Access
- 1 December 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 47 (4) , e20250013
Troponin I is an independent marker of cardiovascular mortality risk in chronic kidney disease patients
Introduction: Cardiovascular disease (CVD) is the main cause of death among chronic kidney disease (CKD) patients. However, the cardiovascular (CV) prognostic evaluation in CKD is not established. Despite previous reports establishing troponin as a CV mortality prognosticator in CKD, there is no consensus on its applicability. Moreover, studies on high-sensitivity troponin I (hsTnI) in this context are scarce. We evaluated the association between hsTnI and CV and overall mortality among CKD patients to identify higher CV-risk patients.
- 1 December 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 47 (4) , e20250013
Open AccessTroponin I is an independent marker of cardiovascular mortality risk in chronic kidney disease patients
Introduction: Cardiovascular disease (CVD) is the main cause of death among chronic kidney disease (CKD) patients. However, the cardiovascular (CV) prognostic evaluation in CKD is not established. Despite previous reports establishing troponin as a CV mortality prognosticator in CKD, there is no consensus on its applicability. Moreover, studies on high-sensitivity troponin I (hsTnI) in this context are scarce. We evaluated the association between hsTnI and CV and overall mortality among CKD patients to identify higher CV-risk patients.
- 25 October 2025
- Published by SAGE Publications in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
Comparison of three strategies (urgent vs. early vs. planned-start) of peritoneal dialysis initiation in kidney failure patients requiring dialysis
Introduction: The clinical outcomes of starting peritoneal dialysis (PD) in kidney failure patients according to different break-in periods are not well established. Our aim was to assess whether the strategy of PD initiation interferes with clinical outcomes over the initial 180 days. Methods: This retrospective study included incident kidney failure patients starting PD at a single center (November 2016–July 2022). Patients were divided into three groups: (1) Urgent-start (US-PD), initiated within 3 days after catheter insertion without prior hemodialysis (HD); (2) Early-start (ES-PD), initiated between 3–14 days, including those with ≤30 days of prior HD; (3) Planned-start (Plan-PD), initiated after 15 days without prior HD. Mechanical and infectious complications, hospitalizations, mortality, and time on PD were compared at 180 days. Patient dropout was defined as the discontinuation of PD due to death or transfer to HD. Results: A total of 211 patients were included: 118 (55.9%) US-PD, 46 (21.9%) ES-PD, and 47 (22.2%) Plan-PD. Among ES-PD patients, 15 (32.6%) had prior HD (<30 days – median time 19 days). Catheter insertion was mostly performed by nephrologists (60.6%) using the modified Seldinger technique (59.2%). Early complications included catheter dysfunction, which occurred in 12.7% of the overall cohort (17.8% in US-PD vs. 4.3% in ES-PD vs. 8.5% in Plan-PD; p = 0.04), and leakage, observed in 7.1% of the overall cohort (9.3% in US-PD vs. 6.5% in ES-PD vs. 2.1% in Plan-PD; p = 0.26). Later complications, hospitalizations, mortality, and time on PD did not differ significantly between groups. Peritonitis, poor education, and hospitalization were associated with dropout. Conclusion: Although initiating PD within 72 h of catheter insertion was associated with more mechanical complications in our study, it resulted in similar clinical outcomes to Planned-start PD patients within the first 6 months of therapy, making it a viable option for urgent dialysis initiation in kidney failure patients.
- 25 October 2025
- Published by SAGE Publications in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
Comparison of three strategies (urgent vs. early vs. planned-start) of peritoneal dialysis initiation in kidney failure patients requiring dialysis
Introduction: The clinical outcomes of starting peritoneal dialysis (PD) in kidney failure patients according to different break-in periods are not well established. Our aim was to assess whether the strategy of PD initiation interferes with clinical outcomes over the initial 180 days. Methods: This retrospective study included incident kidney failure patients starting PD at a single center (November 2016–July 2022). Patients were divided into three groups: (1) Urgent-start (US-PD), initiated within 3 days after catheter insertion without prior hemodialysis (HD); (2) Early-start (ES-PD), initiated between 3–14 days, including those with ≤30 days of prior HD; (3) Planned-start (Plan-PD), initiated after 15 days without prior HD. Mechanical and infectious complications, hospitalizations, mortality, and time on PD were compared at 180 days. Patient dropout was defined as the discontinuation of PD due to death or transfer to HD. Results: A total of 211 patients were included: 118 (55.9%) US-PD, 46 (21.9%) ES-PD, and 47 (22.2%) Plan-PD. Among ES-PD patients, 15 (32.6%) had prior HD (<30 days – median time 19 days). Catheter insertion was mostly performed by nephrologists (60.6%) using the modified Seldinger technique (59.2%). Early complications included catheter dysfunction, which occurred in 12.7% of the overall cohort (17.8% in US-PD vs. 4.3% in ES-PD vs. 8.5% in Plan-PD; p = 0.04), and leakage, observed in 7.1% of the overall cohort (9.3% in US-PD vs. 6.5% in ES-PD vs. 2.1% in Plan-PD; p = 0.26). Later complications, hospitalizations, mortality, and time on PD did not differ significantly between groups. Peritonitis, poor education, and hospitalization were associated with dropout. Conclusion: Although initiating PD within 72 h of catheter insertion was associated with more mechanical complications in our study, it resulted in similar clinical outcomes to Planned-start PD patients within the first 6 months of therapy, making it a viable option for urgent dialysis initiation in kidney failure patients.
- Open Access
- 1 June 2022
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 44 (2) , 196-203
Safety and efficacy of arteriovenous fistula angioplasties performed by nephrologists: report from a Brazilian interventional nephrology center
Introduction: Arteriovenous fistulas (AVF) are the first choice vascular access for hemodialysis. However, they present a high incidence of venous stenosis leading to thrombosis. Although training in interventional nephrology may improve accessibility for treatment of venous stenosis, there is limited data on the safety and efficacy of this approach performed by trained nephrologists in low-income and developing countries. Methods: This study presents the retrospective results of AVF angioplasties performed by trained nephrologists in a Brazilian outpatient interventional nephrology center. The primary outcome was technical success rate (completion of the procedure with angioplasty of all stenoses) and secondary outcomes were complication rates and overall AVF patency. Findings: Two hundred fifty-six angioplasties were performed in 160 AVF. The technical success rate was 88.77% and the main cause of technical failure was venous occlusion (10%). The incidence of complications was 13.67%, with only one patient needing hospitalization and four accesses lost due to the presence of hematomas and/or thrombosis. Grade 1 hematomas were the most frequent complication (8.2%). The overall patency found was 88.2 and 80.9% at 180 and 360 days after the procedure, respectively. Conclusion: Our findings suggest that AVF angioplasty performed by trained nephrologists has acceptable success rates and patency, with a low incidence of major complications as well as a low need for hospitalization.
- 1 June 2022
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 44 (2) , 196-203
Open AccessSafety and efficacy of arteriovenous fistula angioplasties performed by nephrologists: report from a Brazilian interventional nephrology center
Introduction: Arteriovenous fistulas (AVF) are the first choice vascular access for hemodialysis. However, they present a high incidence of venous stenosis leading to thrombosis. Although training in interventional nephrology may improve accessibility for treatment of venous stenosis, there is limited data on the safety and efficacy of this approach performed by trained nephrologists in low-income and developing countries. Methods: This study presents the retrospective results of AVF angioplasties performed by trained nephrologists in a Brazilian outpatient interventional nephrology center. The primary outcome was technical success rate (completion of the procedure with angioplasty of all stenoses) and secondary outcomes were complication rates and overall AVF patency. Findings: Two hundred fifty-six angioplasties were performed in 160 AVF. The technical success rate was 88.77% and the main cause of technical failure was venous occlusion (10%). The incidence of complications was 13.67%, with only one patient needing hospitalization and four accesses lost due to the presence of hematomas and/or thrombosis. Grade 1 hematomas were the most frequent complication (8.2%). The overall patency found was 88.2 and 80.9% at 180 and 360 days after the procedure, respectively. Conclusion: Our findings suggest that AVF angioplasty performed by trained nephrologists has acceptable success rates and patency, with a low incidence of major complications as well as a low need for hospitalization.
- 16 June 2021
- Published by Springer Nature in International Urology and Nephrology
- Vol. 54 (1) , 193-199
Evaluation of central venous catheter and other risk factors for mortality in chronic hemodialysis patients with COVID-19 in Brazil
Purpose Hemodialysis patients with COVID-19 are at increased risk of death. We aimed to describe the characteristics of a cohort of Brazilian hemodialysis patients with COVID-19 and assess their mortality rate and risk factors for death. Methods Retrospective cohort study of 741 Brazilian hemodialysis patients with confirmed COVID-19 from Feb–Dec/2020, of 52 dialysis centers of the country. We analyzed comorbid conditions, sociodemographic factors, and dialysis-related parameters. To detect risk factors for mortality in hemodialysis patients, we performed multivariable Cox proportional hazard regression analysis. Survival was analyzed by Kaplan–Meier. Results From 9877 hemodialysis patients, 741 were diagnosed with COVID-19. Mean age was 57 ± 16 years, 61% were male, and 51% white. The most frequent symptoms were fever (54.1%), cough (50.9%), and dyspnea (37.2%); 14.2% were asymptomatic. There were 139 deaths (18.8%), with 66% within the disease’s first 15 days. 333 patients (44.9%) required hospitalization, and 211 (28.5%) were admitted to an intensive care unit. The cumulative probability of survival at 90 days of diagnosis was 79% (95% CI 76–82%). In the fully adjusted multivariate model, the risk factors significantly associated with death were diabetes mellitus (HR 1.52, 95% CI 1.05–2.19, P = 0.026), use of a central venous catheter (CVC) (HR 1.79, 95% CI 1.22–2.64, P = 0.003), age (HR 1.03, 95% CI 1.01–1.04, P < 0.001), and origin from the North vs. Southeast region (HR 2.60, 95% CI 1.01–6.68, P = 0.047). Conclusions Hemodialysis patients using a CVC as the vascular access, aside from diabetic and elderly ones, should be closely monitored due to their high risk of death in the course of the COVID-19.
- 16 June 2021
- Published by Springer Nature in International Urology and Nephrology
- Vol. 54 (1) , 193-199
Evaluation of central venous catheter and other risk factors for mortality in chronic hemodialysis patients with COVID-19 in Brazil
Purpose Hemodialysis patients with COVID-19 are at increased risk of death. We aimed to describe the characteristics of a cohort of Brazilian hemodialysis patients with COVID-19 and assess their mortality rate and risk factors for death. Methods Retrospective cohort study of 741 Brazilian hemodialysis patients with confirmed COVID-19 from Feb–Dec/2020, of 52 dialysis centers of the country. We analyzed comorbid conditions, sociodemographic factors, and dialysis-related parameters. To detect risk factors for mortality in hemodialysis patients, we performed multivariable Cox proportional hazard regression analysis. Survival was analyzed by Kaplan–Meier. Results From 9877 hemodialysis patients, 741 were diagnosed with COVID-19. Mean age was 57 ± 16 years, 61% were male, and 51% white. The most frequent symptoms were fever (54.1%), cough (50.9%), and dyspnea (37.2%); 14.2% were asymptomatic. There were 139 deaths (18.8%), with 66% within the disease’s first 15 days. 333 patients (44.9%) required hospitalization, and 211 (28.5%) were admitted to an intensive care unit. The cumulative probability of survival at 90 days of diagnosis was 79% (95% CI 76–82%). In the fully adjusted multivariate model, the risk factors significantly associated with death were diabetes mellitus (HR 1.52, 95% CI 1.05–2.19, P = 0.026), use of a central venous catheter (CVC) (HR 1.79, 95% CI 1.22–2.64, P = 0.003), age (HR 1.03, 95% CI 1.01–1.04, P < 0.001), and origin from the North vs. Southeast region (HR 2.60, 95% CI 1.01–6.68, P = 0.047). Conclusions Hemodialysis patients using a CVC as the vascular access, aside from diabetic and elderly ones, should be closely monitored due to their high risk of death in the course of the COVID-19.
- Open Access
- 1 June 2021
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 43 (2) , 236-253
Consensus on the standard terminology used in the nutrition care of adult patients with chronic kidney disease
This nutrition consensus document is the first to coordinate the efforts of three professional organizations - the Brazilian Association of Nutrition (Asbran), the Brazilian Society of Nephrology (SBN), and the Brazilian Society of Parenteral and Enteral Nutrition (Braspen/SBNPE) - to select terminology and international standardized tools used in nutrition care. Its purpose is to improve the training delivered to nutritionists working with adult patients with chronic kidney disease (CKD). Eleven questions were developed concerning patient screening, care, and nutrition outcome management. The recommendations set out in this document were developed based on international guidelines and papers published in electronic databases such as PubMed, EMBASE(tm), CINHAL, Web of Science, and Cochrane. From a list of internationally standardized terms, twenty nutritionists selected the ones they deemed relevant in clinical practice involving outpatients with CKD. The content validity index (CVI) was calculated with 80% agreement in the answers. The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework was used to assess the strength of evidence and recommendations. A total of 107 terms related to Nutrition Assessment and Reassessment, 28 to Diagnosis, nine to Intervention, and 94 to Monitoring and Evaluation were selected. The list of selected terms and identified tools will be used in the development of training programs and the implementation of standardized nutrition terminology for nutritionists working with patients with chronic kidney disease in Brazil.
- 1 June 2021
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 43 (2) , 236-253
Open AccessConsensus on the standard terminology used in the nutrition care of adult patients with chronic kidney disease
This nutrition consensus document is the first to coordinate the efforts of three professional organizations - the Brazilian Association of Nutrition (Asbran), the Brazilian Society of Nephrology (SBN), and the Brazilian Society of Parenteral and Enteral Nutrition (Braspen/SBNPE) - to select terminology and international standardized tools used in nutrition care. Its purpose is to improve the training delivered to nutritionists working with adult patients with chronic kidney disease (CKD). Eleven questions were developed concerning patient screening, care, and nutrition outcome management. The recommendations set out in this document were developed based on international guidelines and papers published in electronic databases such as PubMed, EMBASE(tm), CINHAL, Web of Science, and Cochrane. From a list of internationally standardized terms, twenty nutritionists selected the ones they deemed relevant in clinical practice involving outpatients with CKD. The content validity index (CVI) was calculated with 80% agreement in the answers. The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) framework was used to assess the strength of evidence and recommendations. A total of 107 terms related to Nutrition Assessment and Reassessment, 28 to Diagnosis, nine to Intervention, and 94 to Monitoring and Evaluation were selected. The list of selected terms and identified tools will be used in the development of training programs and the implementation of standardized nutrition terminology for nutritionists working with patients with chronic kidney disease in Brazil.
- Open Access
- 1 June 2021
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 43 (2) , 217-227
Brazilian dialysis survey 2019
Introduction: National data on chronic dialysis treatment are essential for the development of health policies that aim to improve the treatment of patients. Objective: To present data from the Brazilian Dialysis Survey 2019, promoted by the Brazilian Society of Nephrology. Methods: Data collection from dialysis units in the country through a completed online questionnaire for 2019. Results: 314 (39%) centers responded the questionnaire. In July 2019, the estimated total number of patients on dialysis was 139,691. Estimates of the prevalence and incidence rates of patients undergoing dialysis treatment per million of the population (pmp) were 665 and 218, respectively, with mean annual increases of 25 pmp and 14 pmp for prevalence and incidence, respectively. The annual gross mortality rate was 18.2%. Of the prevalent patients, 93.2% were on hemodialysis and 6.8% on peritoneal dialysis; and 33,015 (23.6%) on the waiting list for transplantation. 55% of THE centers offered treatment with peritoneal dialysis. Venous catheters were used as access in 24.8% of THE patients on hemodialysis. 17% of the patients had K ≥ 6.0mEq/L; 2.5% required red blood cell transfusion in July 2019 and 10.8% of the patients had serum levels of 25-OH vitamin D < 20 ng/mL. Conclusion: The absolute number of patients, the incidence and prevalence rates in dialysis in the country continue to increase, as well as the percentage of patients using venous catheter as dialysis access. There was an increase in the number of patients on the list for transplantation and a tendency to reduce gross mortality.
- 1 June 2021
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 43 (2) , 217-227
Open AccessBrazilian dialysis survey 2019
Introduction: National data on chronic dialysis treatment are essential for the development of health policies that aim to improve the treatment of patients. Objective: To present data from the Brazilian Dialysis Survey 2019, promoted by the Brazilian Society of Nephrology. Methods: Data collection from dialysis units in the country through a completed online questionnaire for 2019. Results: 314 (39%) centers responded the questionnaire. In July 2019, the estimated total number of patients on dialysis was 139,691. Estimates of the prevalence and incidence rates of patients undergoing dialysis treatment per million of the population (pmp) were 665 and 218, respectively, with mean annual increases of 25 pmp and 14 pmp for prevalence and incidence, respectively. The annual gross mortality rate was 18.2%. Of the prevalent patients, 93.2% were on hemodialysis and 6.8% on peritoneal dialysis; and 33,015 (23.6%) on the waiting list for transplantation. 55% of THE centers offered treatment with peritoneal dialysis. Venous catheters were used as access in 24.8% of THE patients on hemodialysis. 17% of the patients had K ≥ 6.0mEq/L; 2.5% required red blood cell transfusion in July 2019 and 10.8% of the patients had serum levels of 25-OH vitamin D < 20 ng/mL. Conclusion: The absolute number of patients, the incidence and prevalence rates in dialysis in the country continue to increase, as well as the percentage of patients using venous catheter as dialysis access. There was an increase in the number of patients on the list for transplantation and a tendency to reduce gross mortality.
- Open Access
- 1 March 2021
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 43 (1) , 68-73
Point-of-care ultrasonography in nephrology: a cross-sectional national survey among Brazilian nephrologists
Introduction: Point-of-care ultrasonography (US) (POCUS) has been used in several specialties, particularly in medical emergency. Despite the confirmation of its numerous benefits, the use of POCUS is still timid in nephrology. In the present study, we aim to investigate the use of POCUS by Brazilian nephrologists. Methods: A survey carried out among the members of the Brazilian Society of Nephrology, through institutional e-mail, using the SurveyMonkey platform. We included 12 self-administered questions, which answers were given anonymously. Results: It was evident that the majority (64%) of the participants did not have the opportunity to practice US during their nephrological training in their residency, specialization, or even in internships; those with experience with US use the method mainly for implanting central vascular accesses (68%), performing a renal biopsy (58%) and evaluating renal morphology (50%); and the main barriers for nephrologists who do not yet use US are the high price of US machines (26%) and the lack of time to learn about US (23%). Also, POCUS use for examinations of other organs, such as the lung (31%) and heart (18%), which are fundamental in the cardiovascular and volume assessment of patients with kidney diseases, is even more limited. However, 95% of the participants expressed an interest in learning POCUS for use in their medical practice. Conclusion: Most of the Brazilian nephrologists interviewed were not trained in US; however, almost all of the research participants expressed an interest in learning to use POCUS in nephrological practice.
- 1 March 2021
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 43 (1) , 68-73
Open AccessPoint-of-care ultrasonography in nephrology: a cross-sectional national survey among Brazilian nephrologists
Introduction: Point-of-care ultrasonography (US) (POCUS) has been used in several specialties, particularly in medical emergency. Despite the confirmation of its numerous benefits, the use of POCUS is still timid in nephrology. In the present study, we aim to investigate the use of POCUS by Brazilian nephrologists. Methods: A survey carried out among the members of the Brazilian Society of Nephrology, through institutional e-mail, using the SurveyMonkey platform. We included 12 self-administered questions, which answers were given anonymously. Results: It was evident that the majority (64%) of the participants did not have the opportunity to practice US during their nephrological training in their residency, specialization, or even in internships; those with experience with US use the method mainly for implanting central vascular accesses (68%), performing a renal biopsy (58%) and evaluating renal morphology (50%); and the main barriers for nephrologists who do not yet use US are the high price of US machines (26%) and the lack of time to learn about US (23%). Also, POCUS use for examinations of other organs, such as the lung (31%) and heart (18%), which are fundamental in the cardiovascular and volume assessment of patients with kidney diseases, is even more limited. However, 95% of the participants expressed an interest in learning POCUS for use in their medical practice. Conclusion: Most of the Brazilian nephrologists interviewed were not trained in US; however, almost all of the research participants expressed an interest in learning to use POCUS in nephrological practice.